Hypersensitivity Clinical Trial
— TRO-b-lactOfficial title:
Oral Beta-lactam Drug Reintroduction Protocol, Without Previous Skin Tests, in Children Under 16 Years of Age With a Clinical History That is Not Suggestive of Immunoglobulin E (IgE)-Mediated Anaphylaxis or Toxidermia to Beta-lactams.
The purpose of this study is to establish the rationale for the practice of performing an oral reintroduction test without previous skin tests in children at low risk of IgE-mediated reaction or drug-induced toxidermia, and to confirm the criteria for a drug reintroduction test could be performed without previous skin tests, without subsequent risk of reaction for the child. The primary endpoint will be the risk of a severe IgE-mediated or delayed hypersensitivity reaction in children who received beta-lactam drug reintroduction protocol prior to skin testing.
Status | Not yet recruiting |
Enrollment | 200 |
Est. completion date | July 30, 2019 |
Est. primary completion date | July 30, 2019 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | N/A to 16 Years |
Eligibility |
Inclusion Criteria: - Children under 16 years of age coming for a consultation for a beta-lactam oral reintroduction test. Exclusion Criteria: - Refusal of the legal representatives of the subject for their child to participate in the study, - If his age permits, refusal of the subject to participate in the study, - Subject aged over 16, - Pregnancy, - Absence of affiliation of the subject to a social security scheme, - Skin tests with incriminated beta-lactam already made before the consultation, - Existence of contraindications to the realization of oral reintroduction drug test with the suspected antibiotic, - Existence of criteria in the initial reaction suggestive of a non-low risk of IgE-mediated or delayed hypersensitivity to the incriminated beta-lactam, Taking antihistamine, corticosteroids or beta-blockers within 5 days prior to the oral reintroduction drug test, - Travel abroad of the child scheduled within 7 days of the oral reintroduction drug test. |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Nantes University Hospital |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | low risk of 2% IgE-mediated or severe delayed hypersensitivity reactions following an oral beta-lactam drug reintroduction | Demonstrate a low risk of 2% IgE-mediated or severe delayed hypersensitivity reactions following an oral beta-lactam drug reintroduction, without previous skin tests, in children selected by a questionnaire as being at low risk of IgE-mediated or delayed | At the end of the study, after 2 years. | |
Secondary | Risk evaluation | Evaluate a risk of IgE-mediated or delayed non-severe hypersensitivity reactions. | At the end of the study, after 2 years. | |
Secondary | explain the occurrence of a reaction of IgE-mediated or delayed hypersensitivity | If an IgE-mediated or delayed hypersensitivity reaction (s), severe or not, occurs during the oral beta-lactam drug reintroductions, analyze all the information collected in the inclusion questionnaire (s) of the patient (s) concerned, in order to find the element (s) most likely to explain the occurrence of a reaction of IgE-mediated or delayed hypersensitivity despite initial selection of patients at low risk of reaction. | At the end of the study, after 2 years. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04531540 -
Study to Determine Skin Irritation and/or Sensitization Potential of an Antifungal Cream Containing Trolamine (Repeated Insult Patch Test)
|
Phase 3 | |
Completed |
NCT00988065 -
Sugammadex Hypersensitivity Study (Study P06042)
|
Phase 1 | |
Completed |
NCT03563066 -
Effect of Benralizumab in Atopic Dermatitis
|
Phase 2 | |
Completed |
NCT02588326 -
Sensitivity of Pharmacokinetics to Differences in Particle Size Distribution of Suspension-based Nasal Sprays
|
Phase 1 | |
Completed |
NCT02916888 -
A Study Comparing the Quality of Life of Patients in the Treatment of Eczema by Pediatric Generalists and Specialists
|
N/A | |
Completed |
NCT02360072 -
Airway Inflammation and Bronchial Hyperresponsiveness in Rhinitic Children With or Without Asthma
|
||
Completed |
NCT02352168 -
Airway Inflammation in Children With Allergic Rhinitis and Intervention
|
N/A | |
Completed |
NCT01904604 -
Peanut Epicutaneous Phase II Immunotherapy Clinical Trial
|
Phase 2 | |
Completed |
NCT01494649 -
Pilot Study to Investigate the Efficacy of a Toothpaste in Providing Relief From Dentinal Hypersensitivity
|
N/A | |
Enrolling by invitation |
NCT05039229 -
Measures for Bioaerosol Reduction in the Salmon Industry
|
N/A | |
Enrolling by invitation |
NCT05675241 -
Characterizing the Inflammation Around Dental Implants
|
||
Completed |
NCT04006106 -
Defining ENDOtypes in Perioperative Hypersensitivity by Extensive Cellular and Molecular PHENotyping (ENDOPHEN)
|
||
Completed |
NCT04605471 -
A Study to Learn More About the Safety of Ultravist in Children and in the Elderly
|
||
Completed |
NCT03720470 -
Study Evaluating Efficacy and Safety of PF-04965842 and Dupilumab in Adult Subjects With Moderate to Severe Atopic Dermatitis on Background Topical Therapy
|
Phase 3 | |
Terminated |
NCT05247567 -
Quaternary Ammonium and Immunization in Hairdressers
|
N/A | |
Completed |
NCT05119751 -
Vestibular Versus Sublingual Route of AIT Tablets
|
Phase 4 | |
Recruiting |
NCT06065137 -
Standardised Drug Provocation Testing in Perioperative Hypersensitivity
|
N/A | |
Active, not recruiting |
NCT05960266 -
Immunological Analysis of Lymph Node Tissue After Intralymphatic Immunotherapy: A Prospective Case Control Study
|
Early Phase 1 | |
Not yet recruiting |
NCT04485299 -
Clinical Assessment of Bifluorid 10 vs Varnish Fluoride on The Exposed Hypersensitive Cervical Dentin in Adult Patient
|
Phase 2/Phase 3 | |
Completed |
NCT02686827 -
DBPC-Dose-finding-trial of Vitamin D3 for SCIT in Birch Pollen Allergic Patients.
|
Phase 2 |